Location of Repository

Antiangiogenic and Antitumor Effects of Trypanosoma cruzi Calreticulin

By Nandy C. López, Carolina Valck, Galia Ramírez, Margarita Rodríguez, Carolina Ribeiro, Juana Orellana, Ismael Maldonado, Adriana Albini, Daniel Anacona, David Lemus, Lorena Aguilar, Wilhelm J. Schwaeble and Arturo Ferreira

Abstract

Background: In Latin America, 18 million people are infected with Trypanosoma cruzi, the agent of Chagas' disease, with the greatest economic burden. Vertebrate calreticulins (CRT) are multifunctional, intra- and extracellular proteins. In the endoplasmic reticulum (ER) they bind calcium and act as chaperones. Since human CRT (HuCRT) is antiangiogenic and suppresses tumor growth, the presence of these functions in the parasite orthologue may have consequences in the host/parasite interaction. Previously, we have cloned and expressed T. cruzi calreticulin (TcCRT) and shown that TcCRT, translocated from the ER to the area of trypomastigote flagellum emergence, promotes infectivity, inactivates the complement system and inhibits angiogenesis in the chorioallantoid chicken egg membrane. Most likely, derived from these properties, TcCRT displays in vivo inhibitory effects against an experimental mammary tumor.\ud Methodology and Principal Findings: TcCRT (or its N-terminal vasostatin-like domain, N-TcCRT) a) Abrogates capillary growth in the ex vivo rat aortic ring assay, b) Inhibits capillary morphogenesis in a human umbilical vein endothelial cell (HUVEC) assay, c) Inhibits migration and proliferation of HUVECs and the human endothelial cell line Eahy926. In these assays TcCRT was more effective, in molar terms, than HuCRT: d) In confocal microscopy, live HUVECs and EAhy926 cells, are recognized by FITC-TcCRT, followed by its internalization and accumulation around the host cell nuclei, a phenomenon that is abrogated by Fucoidin, a specific scavenger receptor ligand and, e) Inhibits in vivo the growth of the murine mammary TA3 MTXR tumor cell line.\ud Conclusions/Significance: We describe herein antiangiogenic and antitumor properties of a parasite chaperone molecule, specifically TcCRT. Perhaps, by virtue of its capacity to inhibit angiogenesis (and the complement system), TcCRT is anti-inflammatory, thus impairing the antiparasite immune response. The TcCRT antiangiogenic effect could also explain, at least partially, the in vivo antitumor effects reported herein and the reports proposing antitumor properties for T. cruzi infection

Publisher: Public Library of Science
Year: 2010
DOI identifier: 10.1371/journal.pntd.0000730
OAI identifier: oai:lra.le.ac.uk:2381/8802
Journal:

Suggested articles

Preview

Citations

  1. (1998). Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth. doi
  2. (1999). Calreticulin and calreticulin fragments are endothelial cell inhibitors that suppress tumor growth.
  3. (2008). Suppression of lung tumor growth and metastasis in mice by adeno-associated virus-mediated expression of vasostatin. doi
  4. (2007). Combination of vasostatin and cyclophosphamide in the therapy of murine melanoma tumors.
  5. (2002). Anti-tumor activities of the angiogenesis inhibitors interferon-inducible protein-10 and the calreticulin fragment vasostatin. doi
  6. (2005). An in vivo role for Trypanosoma cruzi calreticulin in antiangiogenesis. doi
  7. (2003). Angiogenesis assays: a critical overview.
  8. (2001). Anticancer properties of flagellate protozoan Trypanosoma cruzi Chagas,
  9. (2001). Chronic Trypanosoma cruzi infection associated with low incidence of 1,2-dimethylhydrazine-induced colon cancer in rats. doi
  10. (2007). Inhibition of Lewis lung carcinoma growth by Toxoplasma gondii through induction of Th1 immune responses and inhibition of angiogenesis. doi
  11. (1953). Microbiology and cancer therapy; a review.
  12. (1976). Culture of vascular endothelium. doi
  13. (2009). Trypanosoma cruzi calreticulin: a possible role in Chagas’ disease autoimmunity. doi
  14. (1990). Ottinetti A
  15. (2001). Oligomerization-dependent regulation of motility and morphogenesis by the collagen XVIII NC1/endostatin domain. doi
  16. (1994). Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. doi
  17. (2003). Scavenger receptor-A mediates gp96/GRP94 and calreticulin internalization by antigen-presenting cells. doi
  18. (2003). The heat shock protein Gp96 binds to human neutrophils and monocytes and stimulates effector functions. doi
  19. (1997). Calreticulin is essential for integrin-mediated calcium signalling and cell adhesion. doi
  20. (1999). Ligand-specific, transient interaction between integrins and calreticulin during cell adhesion to extracellular matrix proteins is dependent upon phosphorylation/dephosphorylation events. doi
  21. (2004). Antiangiogenic activity of inositol hexaphosphate (IP6). doi
  22. (2005). Suppression of choroidal neovascularization by intramuscular polymer-based gene delivery of vasostatin. doi
  23. (2006). Treatment of pancreatic carcinoma by adenoviral mediated gene transfer of vasostatin in mice. doi
  24. (2000). Nitric oxide synthase expression, enzyme activity and NO production during angiogenesis in the chick chorioallantoic membrane. doi
  25. (2004). SREC-I, a type F scavenger receptor, is an endocytic receptor for calreticulin. doi
  26. (1997). Expression cloning of a novel scavenger receptor from human endothelial cells. doi
  27. (2002). SREC-II, a new member of the scavenger receptor type F family, trans-interacts with SREC-I through its extracellular domain. doi
  28. (2000). Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation.
  29. (2000). The tumoricidal effect of Trypanosoma cruzi: its intracellular cycle and the immune response of the host. doi
  30. (1948). Trypanosoma cruzi Endotoxin (KR) in the Treatment of Malignant Mouse Tumors. doi

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.